NCT01414114View on ClinicalTrials.gov

Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 5, 2011

Primary Completion Date

May 21, 2012

Study Completion Date

May 21, 2012

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

Etelcalcetide

Administered 3 times a week by bolus injection into the venous line of the dialysis circuit after the end of hemodialysis.

Sponsors
All Listed Sponsors
lead

KAI Pharmaceuticals

INDUSTRY

NCT01414114 - Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder | Biotech Hunter | Biotech Hunter